WASHINGTON, Sept. 1 (UPI) -- The U.S. Food and Drug Administration has rejected a heart drug which a French company hoped would become a blockbuster medication.
The rejection of Multaq, designed to correct irregular heartbeat, came in a "nonapprovable letter" to manufacturer Sanofi-Adventis, the Wall Street Journal reports.
Read more
Friday, September 01, 2006
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment